Scholars Central

Conference abstract

6-thioguanine in vivo selection for hematopoietic stem cell transplantation (HSCT)

Authors: Robert H Schiestl

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Hematopoietic stem cell transplantation (HSCT) is often the only/last treatment option of some malignancies, congenital diseases and bone marrow failure. For efficient engraftment of donor HSCâ??s stem cell niches have to be provided. Here we developed an in vivo selection scheme for HSCT based on the fact that 6-thioguanine (6TG) toxicity is essentially predicated on its HPRT mediated conversion to thioguanine nucleotide and strongly myelosuppressive. At appropriate concentrations 6TG is strongly myeloablative with little toxicity to other tissues. Therefore it is possible to eliminate diseased bone marrow and replace it with healthy donor bone marrow that lacks HPRT. We have shown that only Hprt proficient cells are susceptible to 6-TG allowing selection in favor of Hprt deficient donor HSCâ??s in vivo and that a 4 week selection regimen results in a 95% replacement of the hostâ??s marrow. Engraftment is more robust with 6-TG selection than with radiation. The proposed method offers selection through a less toxic compound (compared to other schemes) hence less side effects, use of smaller, siRNAproducing vectors (therefore potentially more efficient), possible use of non-integrating vectors and less patient discomfort. The general aim of this project is to show that HSCâ??s deficient for HPRT can be selected for in vivo through 6TG administration, that this procedure would be applicable for conditions like hematological malignancies, congenital diseases and bone marrow failure i.e., where HSCT is indicated and to test all aspects of this procedure to eventually allow for phase-1 clinical trials.

Subjects

Haematology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Blood Disorders & Transfusion
  • SubjectHaematology
  • BylineArticles whose byline prints “Robert H Schiestl”